The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...

Recursion is rare among biotechs because it's developing medicines in-house while banking on big AI collaborations and licensing revenue from its platform to stay afloat in the meantime. By mid-2026, ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cancer via a revised deal that ...

Salt Lake City-based biotech Recursion Pharmaceuticals, which is part of the group of companies looking to use AI technology to accelerate drug development, has raised a $121 million Series C ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion can feel like magic until you understand its simple rules: a base case to stop, and a recursive call to repeat. By breaking problems into smaller versions of themselves, recursion makes ...